The Biostatistics Core provides state-of-the-art statistical support for all SARC SPORE projects and investigators. The overall goal ofthe SARC SPORE is to better understand the etiology of sarcoma and its histologies, and to develop biomarkers and M new treatment options for sarcoma patients. The Biostatistics Core will provide statistical consultation and collaboration on all aspects of design, analysis and interpretation of the clinical trials and laboratory experiments. Core personnel will work closely with project leaders to ensure that the Biostatistics Core provides state-of-the-art statistical support. The primary objectives of the Biostatistics Core are to: 1. Provide study design and review all laboratory, animal, and clinical studies including feasibility assessment, power analysis, and sample size estimation; 2. Collaborate in the project data analysis, interpretation of results, and writing of final study reports and manuscripts; 3. Facilitate prospective collection, entry and quality control of data for the basic science experiments; and collaborate with the clinical trials core to facilitate quality control of clinical data;and 4. Develop and evaluate statistical methods for experimental design and data analysis. To ensure those aims are met, constant, regular communication among core personnel of this Biostatistics Core, SPORE projects and other Cores is needed, Regular weeKly conference calis among project and core leaders will review progress on clinical trials, laboratory studies and data analysis, ensure issues are recognized/addressed, and apprise leaders of developments.
The SARC Sarcoma SPORE Biostatistics Core (Core D) is a cross-cutting SPORE resource, which will perform crucial roles in planning, conducting and analyzing translational and clinical sarcoma research in the main projects, other cores (e.g. Clinical Trials Core - Core C), developmental projects, and career development award efforts. Therefore, the Biostatistics Core is relevant, and essential, to achieving the SPORE goals.
|Nakayama, Robert; Zhang, Yi-Xiang; Czaplinski, Jeffrey T et al. (2016) Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget 7:16581-92|
|Goldstein, Seth D; Trucco, Matteo; Bautista Guzman, Wendy et al. (2016) A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. Oncotarget 7:21114-23|
|Schaefer, Inga-Marie; Fletcher, Christopher Dm; Hornick, Jason L (2016) Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol 29:4-13|
|MariÃ±o-EnrÃquez, AdriÃ¡n; BovÃ©e, Judith V M G (2016) Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. Surg Pathol Clin 9:457-73|
|Tang, Qin; Moore, John C; Ignatius, Myron S et al. (2016) Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. Nat Commun 7:10358|
|Bobowski, Nina P; Baker, Laurence H (2016) The University of Michigan Sarcoma Survivorship Clinic: Preventing, Diagnosing, and Treating Chronic Illness for Improved Survival and Long-Term Health. J Adolesc Young Adult Oncol 5:211-4|
|Koehler, K; Liebner, D; Chen, J L (2016) TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol 27:539-43|
|Bid, Hemant K; Phelps, Doris A; Xaio, Linlin et al. (2016) The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther 15:1018-28|
|Simon, Priscilla S; Bardhan, Kankana; Chen, May R et al. (2016) NF-ÎºB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression. Oncotarget 7:23395-415|
|De Rienzo, Assunta; Archer, Michael A; Yeap, Beow Y et al. (2016) Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. Cancer Res 76:319-28|
Showing the most recent 10 out of 86 publications